Current traditional cancer screening is insufficient.
Low Availability
8 in 10
cancer deaths [1] are not covered by conventional screening [2]
Low Accuracy
4 in 10
patients encounter false-positives from other tumor marker screening [3]*
*Cumulative risk of 43.1% false positives over 14 screening exams from other tumor marker screening methods including chest radiograph, flexible sigmoidoscopy, CA-125, and transvaginal ultrasonography for women, and chest radiograph, flexible sigmoidoscopy, PSA, and DRE for men.
Early stage is defined as Stage I and II. Late stage is defined as Stage IV.
Earlier cancer detection saves lives
The 5 year survival rate increases by up to 13.5x when detected in the early stage [4].
Scroll for more →
LucenceINSIGHT is a multi-cancer early detection (MCED)
next-generation sequencing (NGS) blood test that screens for up to 50 cancers with 99% specificity (low false-positives).
The test uses Lucence's mirror barcoding technology to detect ctDNA, ctRNA, and viral DNA. It can then predict tumor location with machine learning.
This is a prescription only screening test.
LucenceINSIGHT does not diagnose cancer. Further confirmatory testing is recommended for positive results.
Available internationally outside the USA.
99%
Specificity [5]
100%
Positive Predictive Value [6]
88%
Tumor Localization Accuracy [5]
LucenceINSIGHT is recommended for patients:
-
aged 40+
-
have elevated risk of cancer (due to family history, diet, and lifestyle)
Boosted detection with Circulating Tumor RNA (ctRNA) Tumor Markers
12.5% relative increase
in sensitivity
for detection of lung, colon and breast cancer with ctRNA + ctDNA
ctRNA are cancer signals shed into the blood by living cancer cells [7]. LucenceINSIGHT now combines ctDNA and ctRNA analysis to enhance cancer signal detection.
The ctRNA tumor marker boost is useful for screening individuals at high-risk:
-
Family history of lung, colon, or breast cancer
-
Heavy smoker
ctRNA tumor marker boost is included with LucenceINSIGHT 50 and available as an optional add-on for LucenceINSIGHT 5, 7, and 12.
#ctRNA is stable at room temperature for 96 hours. *Sensitivity increase calculated as relative improvement over a ctDNA-only approach, based on an initial training dataset of three cancer types (lung, colon, breast) and independently validated on an internal dataset. Magnitude of increase varies by cancer type. †High-risk = family history of lung, colon, or breast cancer, heavy smoker, and other conditions.
Scroll for more →
Downloads
Find out which test is right for you.
References:
-
Bray, F. et al. CA Cancer J. Clin. 2024; 74(3): 229-263. Calculated based on colorectal, cervical and breast cancer data.
-
Only colorectal, cervical, and breast cancer are recommended by public agencies for screening in Singapore and Hong Kong. HealthHub. Screen for Life. Singapore Ministry of Health. https://www.healthhub.sg/programmes/healthiersg-screening/screening-faq#home. Accessed September 15 2025; Hong Kong Cancer Registry. Prevention and screening. https://www.cancer.gov.hk/en/hong_kong_cancer/prevention_and_screening.html#3. Accessed September 15, 2025
-
Croswell, J. et al. Ann. Fam. Med. 2009; 7(3): 212–222.
-
Cancer Stat Facts. NIH NCI SEER. Accessed July 28, 2025. https://seer.cancer.gov/statfacts/.
-
Poh, J. et al. J. Clin. Oncol. 2024; 42(16): e15042. The ctDNA-based LucenceINSIGHT® demonstrated a specificity of 99.0% (310/313 self-declared healthy donors) and an overall sensitivity of 80.9% (233/288 cancer patients). Across the 21 tissue-of-origin classes analyzed, a high confidence prediction could be made in 62.4% (mean 73.6%, range 26.7%-100%) of cases with an overall accuracy of 87.7% (mean 84.9%, range 33.3%-100%).
-
Tucker, S. et al. Ann. Oncol. 2023; 34: S1625-S1626.
-
Stejskal P, et al. Mol Cancer 2023; 22(15).
